ArticleInternational journal of clinical pharmacy2023

Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.

Munenobu Kashiwa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.